FACTORS ASSOCIATED WITH TIME TO DISABILITY PROGRESSION IN PATIENTS WITH MULTIPLE SCLEROSIS

被引:2
|
作者
Arteaga-Noriega, Anibal [1 ,2 ]
Castro-Alvarez, John Fredy [3 ]
Benjumea-Bedoya, Dione [2 ]
Gutierrez-Vargas, Johanna [3 ]
Segura-Cardona, Angela [1 ]
Gonzalez-Gomez, Difariney [4 ]
Zapata-Berruecos, Jose [1 ,5 ]
机构
[1] Univ CES, Epidemiol & Biostat Res Grp, Medellin, Colombia
[2] Remington Univ Corp, Family & Community Hlth Res Grp, Medellin, Colombia
[3] Remington Univ Corp, Neurosci & Aging Res Grp, Medellin, Colombia
[4] Univ Antioquia, Natl Sch Publ Hlth, Medellin, Colombia
[5] Neurol Inst Colombia, Medellin, Colombia
关键词
multiple sclerosis; Multivariate Analysis; disability evaluations; CEREBELLAR CORTEX; DEMYELINATION; DIAGNOSIS;
D O I
10.17843/rpmesp.2022.394.11433
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives. To determine the sociodemographic, clinical and radiological factors associated with time to disability progression in patients with multiple sclerosis (MS). Materials and methods. Cross-sectional descriptive study with an analytical component, based on clinical records of patients at the Neurological Institute of Colombia, between 2013 and 2021. Progression to disability in MS patients was defined as the time to an increase of at least 0.5 points in the EDSS (Expanded Disability Status Scale) score, sustained for at least six months. A Cox regression model was used to estimate the survival function and Hazard Ratios (HR) with their 95% confidence intervals (95% CI). Results. We included 216 patients, of whom 25% progressed to disability, median survival was 78 months (95% CI: 70-83), active lesions (HR = 1.94; 95% CI: 1.10-3.44), cerebellar complications (HR = 2.03; 95% CI: 0. 99-4.16), being male (HR = 2.5; 95% CI: 1.32-4.73), and having neurological diseases (HR = 2.18; 95% CI: 1.03-4.61) were associated as risk factors. While relapsing remitting MS (HR = 0.63; 95% CI: 0.31-1.26) and age at diagnosis less than 40 years (HR = 0.96; 95% CI: 0.53-1.76) were associated as protective factors. . Conclusions. Progression is affected by many factors, and there is no single independent factor.
引用
收藏
页码:442 / 449
页数:8
相关论文
共 50 条
  • [21] Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis
    Wiendl, Heinz
    Meuth, Sven G.
    DRUGS, 2015, 75 (09) : 947 - 977
  • [22] Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis
    Lunemann, Jan D.
    Hegen, Harald
    Villar, Luisa Maria
    Rejdak, Konrad
    Sao-Aviles, Augusto
    Carbonell-Mirabent, Pere
    Sastre-Garriga, Jaume
    Mongay-Ochoa, Neus
    Berek, Klaus
    Martinez-Yelamos, Sergio
    Perez-Miralles, Francisco
    Abdelhak, Ahmed
    Bachhuber, Franziska
    Tumani, Hayrettin
    Lycke, Jan N.
    Rosenstein, Igal
    Alvarez-Lafuente, Roberto
    Castillo-Trivino, Tamara
    Otaegui, David
    Llufriu, Sara
    Blanco, Yolanda
    Sanchez Lopez, Antonio J.
    Garcia Merino, Juan Antonio
    Fissolo, Nicolas
    Gutierrez, Lucia
    Villacieros-Alvarez, Javier
    Monreal, Enric
    Valls-Carbo, Adrian
    Wiendl, Heinz
    Montalban, Xavier
    Comabella, Manuel
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2024, 11 (04):
  • [23] Biochemical markers for identifying risk factors for disability progression in multiple sclerosis
    van Rensburg, S. Janse
    Kotze, M. J.
    Cronje, F. J.
    Davis, W.
    Moremi, K.
    Dashti, M. Jalali Sefid
    Gamieldien, J.
    Geiger, D.
    Rensburg, M.
    van Toorn, R.
    de Klerk, M. J.
    Hon, G. M.
    Matsha, T.
    Hassan, S.
    Erasmus, R. T.
    SOUTH AFRICAN JOURNAL OF PSYCHIATRY, 2013, 19 (03) : 99 - 100
  • [24] Multiple Sclerosis, disability and progression in Pakistan
    Wasay, M.
    Khatri, I.
    Jabeen, K.
    Ali, S.
    Subhan, M.
    Shahbaz, N.
    Ahmed, A.
    Khoso, N.
    Asif, A.
    Fredrikson, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S196 - S196
  • [25] Measuring disability progression in multiple sclerosis
    Achiron, Anat
    JOURNAL OF NEUROLOGY, 2006, 253 (Suppl 6) : 31 - 36
  • [26] Smoking and disability progression in multiple sclerosis
    Hedstrom, Anna Karin
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2020, 20 (08) : 739 - 741
  • [27] Disability progression in aggressive multiple sclerosis
    Menon, Suresh
    Zhu, Feng
    Shirani, Afsaneh
    Oger, Joel
    Freedman, Mark S.
    Tremlett, Helen
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (03) : 456 - 463
  • [28] Measuring disability progression in multiple sclerosis
    Anat Achiron
    Journal of Neurology, 2006, 253 : vi31 - vi36
  • [29] Factors associated with the risk of secondary progression in multiple sclerosis
    Koch, M.
    Uyttenboogaart, M.
    van Harten, A.
    De Keyser, J.
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (06) : 799 - 803
  • [30] MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate
    Casanova, Ignacio
    Dominguez-Mozo, Maria I.
    De Torres, Laura
    Aladro-Benito, Yolanda
    Garcia-Martinez, Angel
    Gomez, Patricia
    Abellan, Sara
    De Antonio, Esther
    Alvarez-Lafuente, Roberto
    BIOMEDICINES, 2023, 11 (10)